Literature DB >> 10920992

[Interleukin-6 and its soluble receptors in human breast cancer].

Y Kuang1, Z Zhang, X Zhang.   

Abstract

OBJECTIVE: To study interleukin-6(IL-6) and its receptors in human breast cancer.
METHODS: Using ELISA method and ABC immunohistochemistry, IL-6 and its receptors were examined in 45 cases of breast cancer, 10 cases of benign breast diseases and 17 cases of healthy women.
RESULTS: High levels of serum IL-6 and its soluble receptors were frequently observed in breast cancer patients. The levels correlated with the stage and axillary lymph node involvement. The positive staining of IL-6, IL-6R alpha, gp130 were 68.9% in neoplasm tissue.
CONCLUSION: IL-6 and its soluble receptors may be important paramenters reflecting the biological behaviour and prognosis of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10920992

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  4 in total

1.  Cryoablation and Meriva have strong therapeutic effect on triple-negative breast cancer.

Authors:  Dinesh Chandra; Arthee Jahangir; Francois Cornelis; Klara Rombauts; Lydie Meheus; Cheryl L Jorcyk; Claudia Gravekamp
Journal:  Oncoimmunology       Date:  2015-05-29       Impact factor: 8.110

2.  E0771 and 4T1 murine breast cancer cells and interleukin 6 alter gene expression patterns but do not induce browning in cultured white adipocytes.

Authors:  Janina V Pearce; Jared S Farrar; Joseph C Lownik; Bin Ni; Shanshan Chen; Tiffany W Kan; Francesco S Celi
Journal:  Biochem Biophys Rep       Date:  2019-03-20

3.  Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases.

Authors:  S H Kim; F Castro; D Gonzalez; P C Maciag; Y Paterson; C Gravekamp
Journal:  Br J Cancer       Date:  2008-08-19       Impact factor: 7.640

Review 4.  Multifaceted Roles of Interleukin-6 in Adipocyte-Breast Cancer Cell Interaction.

Authors:  Jones Gyamfi; Minseob Eom; Ja-Seung Koo; Junjeong Choi
Journal:  Transl Oncol       Date:  2018-02-03       Impact factor: 4.243

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.